Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Phase 2 Study Demonstrated 73% clinical Clearance in the  200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.